The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.

Claims

54 · 5 independent · depth 4

54 granted claims

›1.independentA synergistically active molecular conjugate comprising a salicylate and a fatty acidnwherein the salicylate is selected from the group consisting of …+13

›20.↳ 1A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.d2

›37.↳ 1A method of treating inflammation that is associated with a metabolic disorder selected from the group consisting of Type II diabetes, insulin resista…d2+2

›40.↳ 1A method of treating inflammation of treating inflammation that is associated with an inflammatory bowel disease selected from the group consisting of…d2+2

›43.↳ 1A method of treating inflammation that is associated with a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, amyl…d2+2

›46.↳ 1A method of treating inflammation that is associated with Duchenne's muscular dystrophy comprising administering to a patient in need thereof an effec…d2+2

›2.independentA compound of Formula I,+14

›3.↳ 2A compound of claim 2, wherein W1 and W2 are each NH.d2+4

›8.↳ 2A compound of claim 2, wherein Q is Z.d2

›9.↳ 2A compound of claim 2, wherein Q isd2

›10.↳ 2A compound of claim 2, wherein m is 1 and L is â€”Sâ€”Sâ€” or â€”Oâ€”.d2

›15.↳ 2A method of treating inflammation that is associated with a metabolic disorder selected from the group consisting of Type II diabetes, insulin resista…d2+1

›17.↳ 2A method of treating inflammation that is associated with an inflammatory bowel disease selected from the group consisting of ileitis, ulcerative coli…d2

›18.↳ 2A method of treating inflammation that is associated with a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, amyl…d2

›19.↳ 2A method of treating inflammation that is associated with Duchenne's muscular dystrophy comprising administering to a patient in need thereof an effec…d2

›49.↳ 2A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.d2

›11.independentA compound of Formula III:+10

›12.↳ 11A compound of claim 11, wherein Q is H.d2

›21.↳ 11A method of treating inflammation that is associated with a metabolic disorder selected from the group consisting of Type II diabetes, insulin resista…d2+1

›23.↳ 11A method of treating inflammation associated with an inflammatory bowel disease selected from the group consisting of ileitis, ulcerative colitis, Bar…d2+1

›24.↳ 11A method of treating inflammation associated with a neurodegenerative disorder selected from the group consisting of Alzheimer's disease and multiple …d2+1

›25.↳ 11A method of treating inflammation associated with Duchenne's muscular dystrophy comprising administering to a patient in need thereof an effective amo…d2+1

›50.↳ 11A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.d2

›13.independentA compound of Formula IIIa,+10

›14.↳ 13A compound of claim 13, wherein at least one t is 1, and at least one Q is H.d2

›29.↳ 13A method of treating inflammation that is associated with a metabolic disorder selected from the group consisting of Type II diabetes, insulin resista…d2+1

›31.↳ 13A method of treating inflammation of treating inflammation that is associated with an inflammatory bowel disease selected from the group consisting of…d2+1

›33.↳ 13A method of treating inflammation that is associated with a neurodegenerative disorder selected from the group consisting of Alzheimer's disease and m…d2+1

›35.↳ 13A method of treating inflammation that is associated with Duchenne's muscular dystrophy comprising administering to a patient in need thereof an effec…d2+1

›51.↳ 13A pharmaceutical composition comprising a compound of claim 13 and a pharmaceutically acceptable carrier.d2

›52.independentThe compound+2

Classifications

26 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/60

Section C — Chemistry; metallurgy

C07C69/86
C07C69/65
C07C271/28
C07C69/94
C07D295/192
C07D307/77
C07C275/42
C07C233/55
C07C323/42
C07C233/20
C07C237/22
C07C235/60
C07D207/416
C07C233/49

USPC · US Patent Classification

560/143554/102514/166514/160560/71514/456554/224554/116514/159560/64554/106

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.6 y

1,677 days filing → grant

Office actions

after a restriction

Responses

3 RCE

Interviews

examiner interview summaries

Examiner

Yate K Cutliff

art unit 1672 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 30 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

8 Jul 2008

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 61078983	8 Jul 2008
related publication	US 20100184730 A1	22 Jul 2010

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.